

BD Nexiva™ Closed IV Catheter System

All the time we invested in developing it is the time you will save using it.



Peripheral intravenous (IV) catheter placement is the most common invasive hospital procedure and can lead to catheter-related complications.¹



In the United States, approximately **60-90%** of hospitalised patients receive IV therapy.¹




35-50% of hospitalised patients who receive a peripheral IV therapy experience a catheter-related complication.¹



Catheter-related complications lead to premature **catheter removal** before the end of the intended dwell time.¹

The BD Nexiva™ Closed IV Catheter System has been designed with features to increase dwell times, reduce catheter-related complications, and reduce costs.²⁻⁷



- ① Built-in stabilisation platform
- ② BD Instaflash™ Needle Technology
- ③ BD Vialon™ biomaterial

- ④ Passive safety mechanism
- ⑤ Pre-attached extension set
- ⑥ BD Q-Syte™ Luer Access Split Septum

The BD Nexiva™ Closed IV Catheter System has clinically demonstrated longer dwell times compared to non-integrated catheters.^{2,4,5,7}


① Built-in stabilisation platform




Helps minimise movement and reduces dislodgement by **84%*** which complies with standards and guidelines for catheter stabilisation.^{7,8}

Showed a nominal[†] **26%** reduction in the risk of securement-related complications versus a non-winged catheter.⁷

Resulted in over **50%** reduction in catheter restarts in a hospital survey setting.²



BD Instaflash™ Needle Technology has been clinically demonstrated to significantly improve first-attempt insertion success rates.^{§9,10}



② Multiple catheter insertions require additional healthcare provider time.¹¹

In a 2021 Dutch study, **85%** first-attempt insertion success was achieved vs **79%**.^{§9}

In a 2022 Indian study, **98.7%** first-attempt insertion success was achieved vs **88.9%**.^{§10}


*Compared with B. Braun Introcan Safety® catheter with Bard Statlock® IV Ultra stabilisation device.

†Not statistically significant for superiority (p=0.138), was significant for non-inferiority (P<0.001).

‡Versus an open-system catheter.

§Compared to a non-notched needle.

The BD Nexiva™ Closed IV Catheter System has been clinically proven to reduce catheter-related complications^{2,3,4,6} and risks to healthcare providers.^{3,7}



- 3 Proprietary **BD Vialon™ biomaterial** enables longer dwell times and reduces the chance of mechanical phlebitis by up to **50%**.^{*12,13}



The BD Nexiva™ Closed IV Catheter System:

Clinically proven to provide a **low rate of serious catheter-related complications**, including infection, clotting events, leakage, infiltration and extravasation.^{**2}


53% reduction in the incidence of methicillin-resistant Staphylococcus aureus.^{†3}

The **median time to any adverse event** was **43% longer**.^{‡4}

Demonstrated a **29% reduction in phlebitis rates**.^{‡4,6}



- 4 **Reduced needlestick injuries by 93%** thanks to its passive safety mechanism.³



- 5 **Reduced exposure to blood during insertion by 98%[‡]** thanks to its integrated extension set.⁷

*Compared to an FEP catheter.

**When used in combination with the Sorbaview®2000 dressing (N=43), versus the baseline peripheral IV securement practices (N=37).

†As part of a peripheral IV catheters practice change initiative in a 500-bed teaching hospital.

‡Versus an open-system catheter.

The BD Nexiva™ Closed IV Catheter System has been shown to reduce costs.^{4,5,7}



Led to a cost reduction of up to **€786,257 per year per 1,000 beds.**⁺⁴



There was an **83%** reduction in stabilisation device cost, from **\$3.58 to \$0.61**, and a **total savings of \$1.91** per catheter insertion.⁷

The integrated BD Nexiva™ Closed IV Catheter System has all the features you need in a peripheral IV catheter and helps to:

- ✓ **Increase** dwell times^{2,4,5,7}
- ✓ **Reduce** the risk of catheter-related complications^{2,3,4,6}
- ✓ **Reduce** the risk of needle stick injuries and blood exposure for healthcare providers^{3,7}
- ✓ **Preserve** IV sites and vessel health^{2,4,5,7,12}
- ✓ **Reduce** costs^{4,5,7}
- ✓ **Improves** nurse satisfaction.^{2,7}

*Compared with an open-system catheter.

†Six days (137.1 hours), compared with 96 hours in an open system.

References

1. Helm RE, Klausner JD, Klemperer JD, *et al.* Accepted but unacceptable: peripheral IV catheter failure. *J Infus Nurs.* 2015;38(3):189-203.
2. McNeill E, Hines NL, Phariss R. A Clinical Trial of a New All-in-One Peripheral-Short Catheter. *JAVA.* 2009;14(1):46-51.
3. Easterlow D, Hoddinott P, Harrison S. Implementing and standardising the use of peripheral vascular access devices. *J Clin Nurs.* 2010;19:721-727.
4. González López JL, Arribi Vilela A, Fernández del Palacio E, *et al.* Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study. *J Hosp Infect.* 2014;86(2):117-26.
5. Tamura N, Abe S, Hagimoto K, *et al.* Unfavorable peripheral intravenous catheter replacements can be reduced using an integrated closed intravenous catheter system. *J Vasc Access.* 2014;15(4):257-263.
6. deRoserroll A. Peripheral Intravenous Catheters: Improving Outcomes Through Change in Products, Clinical Practice and Education. *Vasc Access.* 2017;11(1):7-12.
7. Bausone-Gazda D, Lefaiver CA, Walters SA. A randomized controlled trial to compare the complications of 2 peripheral intravenous catheter-stabilization systems. *J Infus Nurs.* 2010;33(6):371-384.
8. Gorski LA, Hadaway L, Hagle ME, *et al.* Infusion Therapy Standards of Practice, 8th Edition. *J Infus Nurs.* 2021;44(1S Suppl 1):S1-S224.
9. Van Loon FH, Timmerman R, den Brok GP, *et al.* The impact of a notched peripheral intravenous catheter on the first attempt success rate in hospitalized adults: Block-randomized trial. *J Vasc Access.* 2022;(2):295-303.
10. Seetharam AM, Raju U, Suresh K. A randomized controlled study to compare first stick success with Instaflash technology: The FIRSST study. *J Vasc Access.* 2022;11297298221080369.
11. Idemoto B, Rowbottom J, Reynolds J, *et al.* The AccuCath Intravenous Catheter System With Retractable Coiled Tip Guidewire and Conventional Peripheral Intravenous Catheters: A Prospective, Randomized, Controlled Comparison. *J Vasc Access.* 2014;19(2):94-102.
12. Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral venous catheters. *Ann Intern Med.* 1991;114:845-854.
13. Dawkins L, Britton D, Johnson I, *et al.* A randomized trial of winged Vialon cannulae and metal butterfly needles. *Int J Palliat Nurs.* 2000;6(3):110-6.



BD.com

BD Switzerland Sàrl, Terre Bonne Park – A4 Route de Crassier 17, 1262 Eysins, Switzerland

BD, the BD Logo, Instaflash, Nexiva, Q-Syte and Vialon are trademarks of Becton, Dickinson and Company or its affiliates.
© 2023 BD. All rights reserved. BD-81350 (02/23)

